PA
EVLV icon

PharVision Advisers’s Evolv Technologies EVLV Stock Holding History

PharVision Advisers’s Portfolio EVLV Stock Details EVLV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-88,022
Closed -$630K – 282
2025
Q4 		$630K Buy
88,022
+15,798
+22% +$112K 0.32% 10
2025
Q3 		$545K Buy
+72,224
New +$527K 0.31% 16

Other funds holding EVLV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SPCM
Stoic Point Capital Management Palo Alto, California $103M AUM
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PharVision Advisers's EVLV Position: Q1 2026 in Review

PharVision Advisers sold out of Evolv Technologies (EVLV) in Q1 2026, closing a stake of 88,022 shares — an estimated $630K sold.

PharVision Advisers first reported a position in EVLV in Q3 2025 and held it in 2 quarters. The position peaked at $630K in Q4 2025. 260 funds tracked by Wall St. Rank hold EVLV as of Q1 2026.

  • PharVision Advisers reported no remaining Evolv Technologies position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 88,022 Evolv Technologies shares in Q1 2026, an estimated $630K.
  • PharVision Advisers first reported a position in Evolv Technologies in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Evolv Technologies position peaked at $630K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Evolv Technologies as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.